Long Acting Injectable
Long Term Clinical Outcome of Patients Using Risperidone Long Acting Injectable: The Romanian e STAR Database
... risperidone long-acting injectable (RLAI) (290) or on an oral antipsychotic (OA) (88) at baseline as required by the local Summary of the Product ...
12
Optimal needle insertion length for intramuscular injection of risperidone long acting injectable (RLAI)
... Therefore, long-acting injectable antip- sychotics are often used in the treatment of these ...antipsychotic long acting injectable medication was the Risperidone long ...
7
Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
... Notes: after adjusting for confounding factors (age, gender, amount of education, duration of illness, cgi-s score, gaF score, and DiePss score), we performed a multivariate logistic regression analysis with a forward ...
7
Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
... of long-acting injectable first-generation antipsychotics (LAI FGA) in the 1960s, and, more recently, of long-acting injectable second-generation antipsychotics (LAI SGA), has ...
9
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
... Abstract: Schizophrenia is a debilitating chronic disease that requires lifelong medical care and supervision. Even with treatment, the majority of patients relapse within 5 years, and suicide may occur in up to 10% of ...
10
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
... Abstract: Long-acting injectable antipsychotics (LAIs) were developed to make treatment easier, improve adherence, and/or signal the clinician when nonadherence ...a long-acting ...
13
Comparative pharmacokinetics of PLGA & PCL based long acting injectable (LAI) risperidone microsphere formulations
... a long‐acting injectable depot (LAI) antipsychotic drug formulations were being ...marketed long-acting parenteral (IM) microsphere dosage form of Risperidone (Risperidal Consta ® , ...
11
Both typical and atypical long-acting injectable antipsychotics in bipolar disorder: a retrospective chart review
... One of the biggest problems in maintenance therapy is to ensure medication compliance. Patient and family education, social skills training, supportive interventions, community-based interventions, cognitive behavioral ...
6
Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
... schizophrenia. Long-acting injectable (LAI) formula- tions provide extended exposure to antipsychotic therapy and have been useful in address- ing treatment ...
5
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
... Aims: Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to efficacy, safety, ...
13
Long-acting injectable antipsychotics: focus on olanzapine pamoate
... esterification. Long-chain esters show high oil solubility and low water solubility. Long-acting injectable formulations of these drugs contain long-chain drug esters (eg, decanoate) ...
7
Evaluating cabotegravir/rilpivirine long acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
... rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but ...
14
Intramuscular Diffusion Status of Risperidone and Aripiprazole Long Acting Injectable (LAI) by Ultrasonography
... The aim of this study was to consider the characteristics of intramuscular diffusion status of ris- peridone and aripiprazole long acting injectable (LAI) by ultrasonography. Subjects were 40 adult ...
8
Impact of atypical long acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis
... AP long-acting injectable ther- apy (LAT) can significantly improve adherence, reduce symptoms, and reduce the risk of relapse and rehospi- talization, particularly for severely ill patients ...in ...
11
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
... to long-acting injection (risperidone followed by RLAI, and risperidone followed by paliperidone ...initiating long-acting injectable treatment in subjects who have not achieved ...
10
<p>Patients’ experiences of long-acting injectable antipsychotics: a qualitative study</p>
... Long-acting injectable antipsychotics (LAIs) have been widely used in the modern treatment of various psychiatric disorders such as schizophrenia and bipolar ...and long-term disability asso- ...
8
The use of long acting injectable antipsychotic medication
... Iyer, S., Banks, N., Roy, M. A., Tibbo, P., Williams, R., Manchanda, R., Chue, P. and Malla, A. (2013) 'A qualitative study of experiences with and perceptions regarding long- acting injectable ...
9
<p>Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential</p>
... rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but ...
14
Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
... Keywords: psychosis, schizophrenia spectrum and other psychotic disorders, bipolar disorder, long-acting injectable antipsychotic drugs, aripiprazole once-monthly, paliperidone o[r] ...
12
Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
... This post hoc analysis was performed with data from a trial that was not specifically designed to study mark- edly to severely ill subjects. In the original trial, study inclusion criteria for symptomatology required ...
10